🔗 Share this article

While the US undertakes sweeping adjustments to its vaccination guidelines, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on Covid shots throughout the global health crisis and has zeroed in on alleged fatalities after COVID-19 vaccination in her short tenure at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities were set to reveal sweeping changes to the pediatric immunization program in December, synchronizing the US with the Danish vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the world with insufficient data for public health gain. The planned update has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the event. She was recently named acting director of the FDA’s CDER, the fifth person to head the center this calendar year.

Consolidating Power at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has frequently advocated for ending some childhood shot schedules in the US so as to align more like Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or management, which has been standard for previous directors of the biologics center. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that former directors who headed the center have had.”

This division has an immense portfolio at the agency, the former commissioner pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those have to be supervised,” she said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the job, which supervises over 5,000 employees. “It is a enormous management job, if you perform it correctly,” she added.

Response and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions are based on flawed assumptions”.

“This background matches the duties of her job,” the official said, noting the time Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a disputed expedited therapy clearance system that reportedly worried her former heads. “By what process are these drugs being chosen for this expedited pathway? Who is making the calls?” Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, except for shots.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, history, critics said. She published a analysis using unverified public submissions to assess the frequency of heart inflammation after Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the incoming federal leadership featured revising guidelines for novel immunizations and halting “optional” immunizations, she said post-election on a audio program. At the FDA, Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccinations.

“She’s an thorough ideologue who starts off with her conclusions and tailors the evidence to retrofit the data in a extremely misleading, dishonest way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|